Al6061 Bulk재에서 압축시험에 의한 상온가공성 분석 및 마찰인자 측정

김국주,박종수,윤존도 경남대학교 신소재연구소 2003 신소재연구 Vol.15 No.2

부피성형(bulk forming)은 가공속도, 소재 회수를 및 가공 후의 조직 미세와 등의 유리한 점이 많아 대량 생산에 적합한 가공 방식이다. 그러나 금형형상과 가공조건들이 적절하지 못할 경우 형상오차 및 연성파괴 등의 성형결함이 발생하게 된다. 이 성형결함 없이 성형될 수 있는 한계를 부피 성형한계(bulk forming limit)라고 하는데, 이것은 가공성(workability)과 의미가 비슷하다. 가공성은 공정종류 금형과 소재사이의 마찰, 변형속도 등에 의해 좌우되므로 예측하기 어렵다. 따라서 본 실험에서는 가공성을 Al6061의 소재에서 가공온도, 마찰 및 변형을 속도에 따른 성형한계도(forming limit diagram)로 작성하여 정량화하고자 하였다. 또 압축시험에서 금형과 소재사이의 마찰효과에 의한 베럴링(barreling) 현상이 생기므로 신빙성 있는 실험결과를 얻기 힘들다. 따라서, 각 마찰조건에서 링 압축시험을 통한 마찰인자를 구해서 압축시험으로 구한 측정웅력을 보정하여 유동웅력(flow stress)을 구하는데 사용하고자 한다. Bulk forming process is widely used for a large plastic deformation in a metal industry, which has a lot of advantages at processing speed, raw material utilization, fine microstructure, etc. But if die shape and process conditions are selected improperly, forming defects can be found due to geometric errors and ductile fracture. Bulk forming limit is defined as it is deformed without these defects which is similar to the workability. Prediction of workability is difficult because of dependence on a type of processes, friction of die and material, deformation rate, etc. Therefore, in this study, forming limit diagram is made depending on forming temperature, friction and strain rate to analyze the workability of A16061 bulk material. Also, it is difficult in measuring of reliable result exactly because the barreling is caused by interfacial friction between die and material at the compression test. So, friction factor is measured at the different friction conditions by ring compression test and then flow stress will be calculated from the measured stress by compression test.

정신분열병 및 정신분열형 장애에 대한 올란자핀의 효과와 안전성

안용민,강대엽,권준수,김창윤,김철응,반건호,신영민,이기철,이동우,이중서,조현상,채정호,김용식 大韓神經精神醫學會 2001 신경정신의학 Vol.40 No.4

연구목적 : 본 다기관 공동임상연구는 국내 환자를 대상으로 새로운 항정신병약물인 올라자핀의 치료 효과와 안전성을 확인하고자 시행되었다. 방 법 : 1999년 7월부터 2000년 3월까지 국내 10개 병원에 방문한 정신분열병 및 정신분열형 장애 105명을 대상으로 비대조 개방 임상연구를 시행하였다. 중등도 이상의 정신병 증상을 지니거나, 부작용으로 약물교체가 필요한 경우 또는 기분장애 증상의 치료가 필요한 환자를 대상으로 하였다. 2∼7일간의 약물 배설기간 후에 1일 10mg의 올란자핀을 투여하였고, 이후로 3∼7일 간격으로 용량을 조절하여 총 8주간 투여하였다. 치료 효과는 PANSS(Positive and Negative Syndrome Scale), BPRS(Brief Psychiatric Rating Scale), CGI(Clinical Global Impression-Severity), MADRS(Montgomery-Asberg Depression Rating Scale), HAM-A(Hamilton Rating Scale for Anxiety)로 판정하였다. 안전성 평가는 자발적인 이상반응 보고, 활력징후와 혈액 검사 및 SAS(Simpson-Angus Scale), BARS(Barnes Akathisia Rating Scale), AIMS(Abnormal Involuntary Movement Scale)척도를 이용하였다. 결 과 : 105명중에서 85.7%인 90명이 8주간의 치료를 완료하였다. 평균 최빈 용량은 일일 16.1(±4.7)mg이었고, 종료시점에서의 BPRS전체 점수가 기저 상태에 비해 40%이상 감소된 반응군은 69.5%이었다. PANSS의 양성 증후군과 일반정신병리 뿐만 아니라 음성 증후군 소척도에서도 유의한 감소를 보였으며, 이 감소들은 치료 초기부터 나타나서 8주간 지속되었다. 43.8%의 피험자가 중등도 이상의 우울증상을 같이 지니고 있었으며, 올란자핀에 의해 MADRS와 HAM-A가 유의하게 감소하였다. 치료 기간 동안에 활력징후에는 뚜렷한 변화가 없었으나 체중은 8주간 지속적으로 증가하였다. SAS와 AIMS는 감소하였으며, 정좌불능증을 제외한 나머지 추체외로 증상의 발생비율도 낮았다. 임상적인 증상이나 징후를 동반하지 않는 ALT/SGPT의 상승을 보였지만 프로락틴을 포함하는 대부분의 혈액 검사상 뚜렷한 이상 변화는 없었다. 결 론 ; 비록 본 임상연구가 비대조 개방 임상연구로서 많은 제한점을 가지고 있지만, 올란자핀이 기존 약물에 내약성을 보이거나 기분증상을 동반하는 정신병에 치료 효과가 있었다. 그리고 기존 항정신병약물 치료시에 문제가 되었던 추체외로 증상과 고프르로락틴 혈증을 포함하는 대부분의 부작용면에서 안전성을 보여 주었다. Objective : This multicenter clinical trial was carried out to investigate the efficacy and the safety of olanzpine for the treatment of Korean patients. Mothod : 105 patients with schizophrenia and schizophreniform disorder, visited at 10 mental or university hospitals, had received an open and non-comparative treatment with olanzapine for 8 weeks. Patients had psychotic or depressive symptoms with the severity above moderate degree or intolerable side effects to previous antipsychotics. After a wash-out period of 2-7 days, 10mg olanzapine was prescribed initially to all the patients, and then the dosage could be adjusted within the range of 5-20mg/day of olanzapine by 3-7 days. Results : 90(85.7%) of 105 patients completed the 8-weeks trial and the mean modal dose of olanzapine was 16.1(±4.7%)mg/day. At the end of the trial, 73 patients(69.5%) were classified as responder, which was defined as 40% or more improvement in BPRS(Brief Psychiatric Rating Scale) score comparing to baseline. There was a significant reduction in the scores of PANSS(Positive and Negative Syndrome Scale)and subscales including negative symptom scores and CGI. Also weekly analysis showed that the reductions in scores were kept on for the whole period of the trial. 43.8% of all the patients had depressive symptoms at the baseline and total scores of MADRS(Montgomery-Asberg Depression Rating Scale) and HAM-A(Hamilton Rating Scale for Anxiety) were also reduced after the trials. Vital signs revealed no clinically significant changes but continuous weight gain was observed during the treatment with olanzapine. The scores of SAS(Simpson-Angus Scale) and AIMS(Abnormal Involuntary Movement Scale) for assessing the EPS(extrapyramidal symptoms)and tardive dyskinesia respectively were significantly decreased and only a few patients reported EPS as adverse events. Although mild and clinically non-significant of ALT/SGPT was observed, most laboratory parameters including plasma prolactin level showed to significant changes during the trial. Conclusions : Although this trial had many limitations because it was a non-comparative and open study, olanzapine showed high efficacy on the positive, negative and depressive symptoms in schizophrenia and schizophreniform disorder.In addition to that, olanzapine showed a substantially favorable safety profile, such as low incidence of EPS and hyperprolactinemia.

A Case of Japanese Encephalitis Presenting with Fever and Seizure in a 7-month old Infant

김수연(Soo Yeon Kim),김존수(Jon Soo Kim),이현주(Hyun Ju Lee),김헌민(Hunmin Kim),임병찬(Byung Chan Lim),황희(Hee Hwang),채종희(Jong-Hee Chae),최지은(Jieun Choi),김기중(Ki Joong Kim),황용승(Yong Seung Hwang) 대한소아신경학회 2013 대한소아신경학회지 Vol.21 No.3

Japenses encephalitis (JE)는 동아시아에서 가장 흔한 뇌염의 원인 중 하나이며 사망률과합병증 발생률이 높은 질환이다. 그러나 최근 국내에서는 국가차원의 예방접종 및 숙주 조절로 인해 JE의 발생빈도가 급격히 줄었으며, 특히 최근 10년간 9세 이하의 소아에서는 보고된 예가 없다. 따라서 소아에서 발생한 뇌염의 원인으로 먼저 고려하지 않는 것이 일반적이나 특징적인 MRI 소견과 함께 혈액 및 뇌척수액의 일본뇌염바이러스 항체 양성으로 진단된 소아의 JE 1례가 발견되었다. 환자는 발병 당시 생후 9개월로, 발열 및 열성경련을 주소로 내원하였으며 이후 경련 및 의식저하가 지속되고 호흡부전 및 자율신경계 기능이상을 동반한 나쁜 경과를 보였으나 스테로이드 및 면역글로불린 치료를 병행하면서 서서히 호전되었다. 이와 같이 특히 접종 이전의 소아에서 특히 특징적인 MRI 이상을 동반한 뇌염의 경우 JE를 반드시 감별해야 하며 의심되는 경우 예후 향상을 위해 스테로이드 및 면역글로불린 등의 치료를 고려할 수 있겠다. Japanese encephalitis is one of the leading causes of acute encephalitis in Asia. But in Korea, the number of Japanese encephalitis cases has dropped considerably due to mass vaccination and vector control. Especially, there were no case reports under the age of 9 years during the last ten years. We will describe a case of a previously healthy 7-month old boy who presented with fever and seizure. The patient was diagnosed with Japanese encephalitis, based on the cerebrospinal fluid and serum antibody analyses for the Japanese encephalitis virus. Typical brain magnetic resonance image findings of Japanese encephalitis were observed. The patient received extensive conservative treatment including high dose intravenous corticosteroid treatment and immunoglobulin. In spite of severe hemodynamic instability, the patient survived, and he is currently in a vegetative state with respiratory assist by a home ventilator. Although the incidence of Japanese encephalitis dropped dramatically in Korea, pediatricians should always consider the diagnosis as one of the possibilities for patients with encephalitis, especially if the patient is not immunized for JEV. Since there is no specific treatment for JEV, timely and comprehensive conservative care is critical to reduce the mortality and morbidity.

Perampanel is also a useful adjunctive treatment option in refractory epilepsy in children

Jon Soo Kim,Won Seop Kim 대한소아청소년과학회 2019 Clinical and Experimental Pediatrics (CEP) Vol.62 No.7

.

Next-generation sequencing is a powerful method to enhance diagnostic yield in global developmental delay/intellectual disability

Kim, Jon Soo The Korean Pediatric Society 2020 Clinical and Experimental Pediatrics (CEP) Vol.63 No.6

Lessons Learned from the Point-of-Care Use of a Facial Analysis Technology

Jon Soo Kim,Hansol Ko,Hyewon Woo,Won Seop Kim 대한소아신경학회 2023 대한소아신경학회지 Vol.31 No.4

Purpose: We aimed to evaluate the utility of facial analysis technology for genetic diagnoses in a typical pediatric genetic clinic. Methods: A retrospective review identified children (aged <18 years) who had not previously received a definitive genetic diagnosis and underwent a comprehensive genetic evaluation. Their photographs and relevant clinical non-facial features were uploaded to the CLINIC application of the Face2Gene web interface, and the resulting analysis was accessed and correlated to the molecular diagnosis. Results: Of the 23 children included, the overall diagnostic yield in this study was 60.9% (14/23). In total, 64.3% of patients had the correct condition suggested in the top 10 differential diagnoses. The gestalt similarity was only 55.6%, but the phenotypic features added by the clinician showed a similarity of more than the medium level in all patients. Conclusion: Our data underscore the usefulness of facial analysis technology as an auxiliary point-of-care tool in pediatric genetic clinics, and we also present some considerations to increase accuracy.

Perampanel is also a useful adjunctive treatment option in refractory epilepsy in children

Kim, Jon Soo,Kim, Won Seop The Korean Pediatric Society 2019 Clinical and Experimental Pediatrics (CEP) Vol.62 No.7

A case of isodicentric chromosome 15 presented with epilepsy and developmental delay

Kim, Jon Soo,Park, Jinyu,Min, Byung-Joo,Oh, Sun Kyung,Choi, Jin Sun,Woo, Mi Jung,Chae, Jong-Hee,Kim, Ki Joong,Hwang, Yong Seung,Lim, Byung Chan The Korean Pediatric Society 2012 Clinical and Experimental Pediatrics (CEP) Vol.55 No.12

We report a case of isodicentric chromosome 15 (idic(15) chromosome), the presence of which resulted in uncontrolled seizures, including epileptic spasms, tonic seizures, and global developmental delay. A 10-month-old female infant was referred to our pediatric neurology clinic because of uncontrolled seizures and global developmental delay. She had generalized tonic-clonic seizures since 7 months of age. At referral, she could not control her head and presented with generalized hypotonia. Her brain magnetic resonance imaging scans and metabolic evaluation results were normal. Routine karyotyping indicated the presence of a supernumerary marker chromosome of unknown origin (47, XX +mar). An array-comparative genomic hybridization (CGH) analysis revealed amplification from 15q11.1 to 15q13.1. Subsequent fluorescence in situ hybridization analysis confirmed a idic(15) chromosome. Array-CGH analysis has the advantage in determining the unknown origin of a supernumerary marker chromosome, and could be a useful method for the genetic diagnosis of epilepsy syndromes associated with various chromosomal aberrations.

Factitious Seizures and Limb Paralysis in Munchausen Syndrome

Jon Soo Kim,Won Seop Kim 대한소아신경학회 2020 대한소아신경학회지 Vol.28 No.3

Recent research trends in Kawasaki disease-related infection

Kim Jon Soo 대한소아청소년과학회 2022 Clinical and Experimental Pediatrics (CEP) Vol.65 No.11

.